Effectiveness of oral glutathione in reducing nitric oxide and IL-1α concentrations for clinical improvement in mild to moderate acne vulgaris: a randomized controlled trial

What Was Tested

The paper reports a study of Glutathione in the context of acne, published as a randomized controlled trial.

Acne vulgaris (AV) is a chronic inflammatory dermatosis predominantly affecting adolescents and young adults.

Oxidative and nitrosative stress, marked by elevated nitric oxide (NO) and interleukin (IL)-1α, contributes to AV pathogenesis.

Who Took Part

The study group was 40 subjects.

The age groups tagged for this paper are teenagers, young adults and adults, both men and women.

A randomized controlled trial was conducted involving 40 subjects diagnosed with mild to moderate AV.

Clinical severity of AV was assessed utilizing the Lehmann criteria.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Glutathione and who got the comparison, which limits bias.

Neither the subjects nor the staff measuring them knew who was on Glutathione, so expectations could not easily colour the readings.

Some subjects received a placebo instead of Glutathione, giving a reference point.

Serum levels of NO and IL-1α were measured at baseline and week 4.

What Was Measured

Topics PubMed links to this paper include Acne Vulgaris, Nitric Oxide, Glutathione, Interleukin-1alpha and Antioxidants.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glutathione in 40 subjects in people with acne.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Acta dermatovenerologica Alpina, Pannonica, et Adriatica), a journal based in Slovenia.

More context: the Glutathione compound page, Acne research.